HUH BEST STUDY CLINICAL TRIAL
Research Goals
2024 Beta-Agonist versus Botox® Trial for Urgency Urinary Incontinence (BEST) Trials: Therapy for Urge Urinary Incontinence
Study Objectives
The goal of our study is to learn what treatment options work best for women with UUI. We will compare an oral medication (Beta-3 Agonist) and a BOTOX® (onabotulinumtoxinA) injection.
-
Beta-3 Agonist medication is an oral medication that causes bladder muscle relaxation and decreases UUI.
-
BOTOX® injections in the bladder also decreases bladder contractions and UUI.
-
Both Beta-3 Agonist medication and BOTOX® are US Food and Drug Administration (FDA) approved for the treatment of UUI.
HUH BEST STUDY CLINICAL TRIAL
Study Participation Information & Criteria
2024 Beta-Agonist versus Botox® Trial for Urgency Urinary Incontinence (BEST) Trials: Therapy for Urge Urinary Incontinence
In total, 432 women across 5 sites in the United States will be asked to participate, including Howard University Hospital. Approximately 87 women will be drawn from Howard University Hospital and its surrounding areas.
Participating sites include:
-
Howard University, Washington, DC
-
University of Alabama, Birmingham, AL
-
University of California San Diego, San Diego, CA
-
University of New Mexico, Albuquerque, NM
-
Women & Infants Hospital of Rhode Island, Providence, RI
Target Participants
Study Compensation
-
At first visit
-
At start of treatment
-
At completion of their 3-month visit
-
At 6th, 9th and 12 months visits
All study participants will be compensated for their participation under the following guidelines:
Most visits can be conducted via the telephone. All clinic visits for both Beta-3 Agonist medication and BOTOX® go through normal clinical care and your health insurance.
Study Eligibility & Participation Length
The study is looking to recruit an ethnic diverse population of (Spanish, Amharic and English) speakers. You may be able to participate if you meet the following study criteria:
-
A woman 18 years or older.
-
Isn't currently pregnant and do not plan to become pregnant during the trial.
-
Have tried anticholinergic medication (e.g., tolteradine (Detrol), oxybutynin (Ditropan) and solifenacin (Vesicare) in the past without improvement.
If you are eligible and say yes to participate, you will be in this study for up to 1 year from the day you begin your first treatment. You will be asked to complete questionnaires on your first visit. You will also be asked to complete questionnaires at the 3rd, 6th, 9th and 12th-month follow-up visits. Study visits may be done either in person, virtually, or over the phone.
HUH BEST STUDY CLINICAL TRIAL
Contact Us Today
2024 Beta-Agonist versus Botox® Trial for Urgency Urinary Incontinence (BEST) Trial: Therapy for Urge Urinary Incontinence
Join the HUH Best Study Clinical Trial
If you are interested in learning more about the HUH "Best Study" Clinical Trial as well as finding out if you are able to participate, please click on the link below. Complete the following questionnaire or contact the research team at gabriela.armendariz@howard.edu, menna.araya@howard.edu; or at the following phone numbers: 202.865.4175 or 202.285.0650.